Louisiana State Employees Retirement System Lowered By $6.14 Million Its Nektar Therapeutics (NKTR) Stake; WHARF HOLDINGS LTD ORDINARY SHARES (WARFF) SI Decreased By 86.78%

June 12, 2018 - By Marguerite Chambers

Nektar Therapeutics (NASDAQ:NKTR) Logo

Louisiana State Employees Retirement System decreased Nektar Therapeutics (NKTR) stake by 85.52% reported in 2018Q1 SEC filing. Louisiana State Employees Retirement System sold 57,900 shares as Nektar Therapeutics (NKTR)’s stock declined 11.70%. The Louisiana State Employees Retirement System holds 9,800 shares with $1.04 million value, down from 67,700 last quarter. Nektar Therapeutics now has $9.09B valuation. The stock decreased 2.07% or $1.12 during the last trading session, reaching $53.02. About 5.27 million shares traded or 28.06% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 271.91% since June 12, 2017 and is uptrending. It has outperformed by 259.34% the S&P500. Some Historical NKTR News: ; 16/04/2018 – In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN); 25/04/2018 – EC OKS BRISTOL-MYERS SQUIBB’S OPDIVO (NIVOLUMAB) FOUR-WEEK DOSI; 26/04/2018 – Opdivo Drives Bristol-Myers Growth — Earnings Review; 25/04/2018 – EC OKS BRISTOL-MYERS SQUIBB’S OPDIVO; 16/04/2018 – OPDIVO PLUS LOW-DOSE YERVOY COMBINATION REDUCES RISK OF PROGRES; 31/05/2018 – NEKTAR THERAPEUTICS ANNOUNCES SUBMISSION OF A NEW DRUG APPLICATION TO THE U.S. FDA FOR NKTR-181, A FIRST-IN-CLASS INVESTIGATIONAL OPIOID TO TREAT CHRONIC LOW BACK PAIN IN ADULT PATIENTS NEW TO OPIOID; 06/03/2018 – Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week; 10/05/2018 – Nektar Therapeutics 1Q Loss/Shr 60c; 18/04/2018 – FDA ACCEPTS BRISTOL-MYERS’ OPDIVO FOR PRIORITY REVIEW IN SCLC; 29/03/2018 – Netflix, biotech Nektar among the biggest market winners in the first quarter

WHARF HOLDINGS LTD ORDINARY SHARES (OTCMKTS:WARFF) had a decrease of 86.78% in short interest. WARFF’s SI was 198,400 shares in June as released by FINRA. Its down 86.78% from 1.50M shares previously. With 4,900 avg volume, 41 days are for WHARF HOLDINGS LTD ORDINARY SHARES (OTCMKTS:WARFF)’s short sellers to cover WARFF’s short positions. The SI to WHARF HOLDINGS LTD ORDINARY SHARES’s float is 0.02%. It closed at $3.37 lastly. It is down 0.00% since June 12, 2017 and is . It has underperformed by 12.57% the S&P500.

The Wharf Limited, through its subsidiaries, engages in property and infrastructure investment in Hong Kong, Singapore, and the People's Republic of China. The company has market cap of $10.02 billion. The companyÂ’s property portfolio comprises office, retail, serviced apartments, and hotels and clubs. It has a 3.67 P/E ratio. It also provides container terminal services.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Fool.com which released: “Why Nektar Therapeutics Stock Stumbled 11.8% Today” on June 08, 2018, also Nasdaq.com with their article: “Here’s Why Nektar Therapeutics Jumped as Much as 17% Today” published on June 06, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on June 11, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Fool.com and their article: “Is Nektar Therapeutics Stock a Bargain Now?” published on June 04, 2018 as well as Fool.com‘s news article titled: “Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today” with publication date: June 06, 2018.

Among 13 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Nektar Therapeutics has $125 highest and $16 lowest target. $72.91’s average target is 37.51% above currents $53.02 stock price. Nektar Therapeutics had 33 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 9 by Roth Capital. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, June 5 report. Jefferies maintained the shares of NKTR in report on Wednesday, August 16 with “Buy” rating. The rating was maintained by Canaccord Genuity on Wednesday, January 10 with “Buy”. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Aegis Capital on Tuesday, November 8. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Roth Capital on Monday, November 13. H.C. Wainwright reinitiated the shares of NKTR in report on Monday, April 2 with “Buy” rating. The rating was maintained by Mizuho with “Buy” on Thursday, March 29. The rating was maintained by Aegis Capital on Monday, June 5 with “Buy”. The rating was maintained by JP Morgan on Monday, June 4 with “Overweight”.

Louisiana State Employees Retirement System increased Facebook Inc (NASDAQ:FB) stake by 1,900 shares to 146,300 valued at $23.38M in 2018Q1. It also upped Neogen Corp (NASDAQ:NEOG) stake by 6,466 shares and now owns 22,866 shares. Fiserv Inc (NASDAQ:FISV) was raised too.

Investors sentiment increased to 1.43 in 2018 Q1. Its up 0.24, from 1.19 in 2017Q4. It is positive, as 23 investors sold NKTR shares while 97 reduced holdings. 99 funds opened positions while 73 raised stakes. 153.40 million shares or 2.02% more from 150.36 million shares in 2017Q4 were reported. Fred Alger Mngmt has invested 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Meeder Asset Management Inc reported 2,006 shares stake. Qs Ltd Liability Co, a New York-based fund reported 5,462 shares. Duquesne Family Office Ltd Liability Corporation stated it has 7% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Ajo Limited Partnership, Pennsylvania-based fund reported 11,824 shares. Eam Investors Ltd Liability Co stated it has 1.13% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Commercial Bank Of Montreal Can owns 104,730 shares. Arizona State Retirement holds 0.04% or 39,900 shares. California State Teachers Retirement reported 229,137 shares stake. Weiss Multi invested in 5,000 shares or 0.02% of the stock. 2,100 are held by Highland Cap Mngmt Ltd Partnership. 350,633 are owned by Parametric Portfolio Assocs Limited Liability Co. Td Asset Mngmt holds 127,620 shares or 0.02% of its portfolio. Exxonmobil Investment Tx reported 0.08% in Nektar Therapeutics (NASDAQ:NKTR). Shell Asset Mngmt reported 20,261 shares.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on August, 14. They expect $5.33 earnings per share, up 1,466.67% or $5.72 from last year’s $-0.39 per share. NKTR’s profit will be $913.60 million for 2.49 P/E if the $5.33 EPS becomes a reality. After $-0.60 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -988.33% EPS growth.

Since December 13, 2017, it had 1 buy, and 34 insider sales for $90.80 million activity. 30,000 shares were sold by KUEBLER CHRISTOPHER A, worth $1.76M on Tuesday, January 2. Another trade for 4,917 shares valued at $410,029 was sold by Nicholson John. Thomsen Jillian B. had sold 3,576 shares worth $298,203 on Wednesday, May 16. $10.93M worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by ROBIN HOWARD W on Tuesday, May 1. 4,060 Nektar Therapeutics (NASDAQ:NKTR) shares with value of $338,563 were sold by Hora Maninder. Labrucherie Gil M sold 90,000 shares worth $7.56M. Another trade for 5,000 shares valued at $290,212 was bought by WHITFIELD ROY A.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>